BeyondSpring Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
BeyondSpring Inc. (BYSI) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.20% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-25
- BeyondSpring Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 0.20%.
- BeyondSpring Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | 0.20% 10-K · filed 2026-03-25 | -0.20% 10-K · filed 2025-03-27 |
| 2023-12-31 | -0.40% 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |